It has been a terrible start to the week for the Cann Group Ltd (ASX: CAN) share price. The cannabis company's shares are currently the worst performers on the All Ordinaries on Monday afternoon.
At one stage they were down by 33% to 49 cents. They have since narrowed this decline slightly, but are still down 27% to 53.5 cents at the time of writing.
As a comparison, the next worst performers are Nufarm Limited (ASX: NUF) and Pacific Current Group Ltd (ASX: PAC). They are down 18% and 8%, respectively, this afternoon.
Why is the Cann Group share price crashing lower?
Investors appear to be selling Cann Group's shares today after looking over the production plans it announced last week.
Previously, the company was planning to complete the Mildura facility in a single stage development. This would give it a total capacity of 70,000 kgs of cannabis flower at an estimated project cost of $184 million.
This was expected to generate annual revenues of approximately $220 million to $280 million
However, in response to weaker than expected demand and an oversupply of cannabis, management intends to split its construction into three stages. It estimates that first stage production will be around 25,000 kgs.
And while management hasn't updated its revenue forecast yet, I suspect the market is anticipating a sharp downgrade. Especially given the abundance of cannabis flower and the limited use that its offtake partner, Aurora Cannabis, has for it at present.
Other cannabis news.
It isn't all doom and gloom in the cannabis industry on Monday. Both AusCann Group Holdings Ltd (ASX: AC8) and Botanix Pharmaceuticals Ltd (ASX: BOT) are up 4.5% following updates this morning.
The AusCann share price is up after appointing TGA-licensed Aspen Pharmacare Australia to provide packaging for its medicinal cannabis pharmaceutical products.
Whereas the Botanix share price is up after following a US DEA announcement. It advised Botanix's partner Purisys, that its synthetic cannabidiol product is no longer scheduled as a controlled substance.
Botanix Executive Chairman, Vince Ippolito, believes this change will make a major difference to the speed of developing its products and greatly reduces the risks and costs of clinical development.
